23 October 2018 : Original article
Everolimus Use for Intolerance or Failure of Baseline Immunosuppression in Adult Heart and Lung Transplantation
Shelby E. Kelsh1ABCDEF, Reda Girgis12ADE, Michael Dickinson12ADE, Jennifer K. McDermott12ABCDEF*DOI: 10.12659/AOT.910952
Ann Transplant 2018; 23:744-750
Abstract
BACKGROUND: Everolimus can be utilized after heart or lung transplantation to reduce calcineurin inhibitor associated nephrotoxicity, due to cell cycle inhibitor adverse effects, and as adjunct therapy for rejection, cardiac allograft vasculopathy, and bronchiolitis obliterans syndrome.
MATERIAL AND METHODS: A single-center, retrospective cohort study was conducted including 51 adult heart transplant patients (n=32) and lung transplant patients (n=19) started on everolimus due to immunosuppressive therapy intolerance or failure, between 2010 and 2017. Everolimus indication, response, efficacy, and tolerability were assessed.
RESULTS: Everolimus was most commonly initiated due to leukopenia/neutropenia (n=17, 33%) or renal dysfunction (n=13, 25%). Leukopenia/neutropenia resolved in 76% of patients (13 out of 17 patients). Renal function (GFR) increased 7.4 mL/min from baseline to 3 months after everolimus initiation (P=0.011). The most common adverse effects were edema (n=23, 45%) and hyperlipidemia (n=25, 49%). A high discontinuation rate was observed (n=21, 41%), mostly from edema.
CONCLUSIONS: Everolimus might be beneficial in heart and lung transplant patients with leukopenia or neutropenia and lead to modest, short-term renal function improvement. Patient selection is crucial because adverse effects frequently lead to everolimus discontinuation.
Keywords: Heart Transplantation, Immunosuppressive Agents, Leukopenia, Lung Transplantation, renal insufficiency
In Press
Original article
The Long-Acting Glucagon-Like Peptide-2 Analog Apraglutide Enhances Intestinal Protection and Survival Afte...Ann Transplant In Press; DOI: 10.12659/AOT.945249
Original article
Biopsychosocial Effects of Donor Traits on Heart Transplant RecipientsAnn Transplant In Press; DOI:
Clinical Research
Ten-Year Retrospective Analysis of Continuous Renal Replacement Therapy in Burn Patients: Impact on Surviva...Ann Transplant In Press; DOI:
Original article
Factors Influencing Stress Disorders in Intensive Care Unit (ICU) Patients After Liver Transplantation: A C...Ann Transplant In Press; DOI: 10.12659/AOT.944320
Most Viewed Current Articles
05 Apr 2022 : Original article 13,113
Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver TransplantationDOI :10.12659/AOT.935604
Ann Transplant 2022; 27:e935604
22 Nov 2022 : Original article 10,260
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...DOI :10.12659/AOT.937988
Ann Transplant 2022; 27:e937988
12 Jan 2022 : Original article 9,611
Risk Factors for Developing BK Virus-Associated Nephropathy: A Single-Center Retrospective Cohort Study of ...DOI :10.12659/AOT.934738
Ann Transplant 2022; 27:e934738
15 Mar 2022 : Case report 7,271
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860